These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs]. Shiba K; Matsumoto T; Hirota S Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796 [TBL] [Abstract][Full Text] [Related]
25. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib. Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246 [TBL] [Abstract][Full Text] [Related]
26. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Gross DJ; Munter G; Bitan M; Siegal T; Gabizon A; Weitzen R; Merimsky O; Ackerstein A; Salmon A; Sella A; Slavin S; Endocr Relat Cancer; 2006 Jun; 13(2):535-40. PubMed ID: 16728580 [TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal stromal tumors. von Mehren M; Watson JC Hematol Oncol Clin North Am; 2005 Jun; 19(3):547-64, vii. PubMed ID: 15939196 [TBL] [Abstract][Full Text] [Related]
29. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352 [TBL] [Abstract][Full Text] [Related]
30. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Bauer S; Duensing A; Demetri GD; Fletcher JA Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049 [TBL] [Abstract][Full Text] [Related]
31. Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols. Ahmed A; Gilbert-Barness E; Lacson A Pediatr Dev Pathol; 2004; 7(4):342-7. PubMed ID: 15383930 [TBL] [Abstract][Full Text] [Related]
32. Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Lankat-Buttgereit B; Hörsch D; Barth P; Arnold R; Blöcker S; Göke R Digestion; 2005; 71(3):131-40. PubMed ID: 15785039 [TBL] [Abstract][Full Text] [Related]
33. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. Shaw TJ; Vanderhyden BC Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414 [TBL] [Abstract][Full Text] [Related]
34. C-kit protein expression in Wilms' tumour: an immunohistochemical study. Giordano G; Campanini N; Rocco A; Donofrio V; Bertolini P; Falleti J; Pettinato G Eur J Surg Oncol; 2009 Jun; 35(6):629-35. PubMed ID: 19010635 [TBL] [Abstract][Full Text] [Related]
35. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Taylor JR; Brownlow N; Domin J; Dibb NJ Oncogene; 2006 Jan; 25(1):147-51. PubMed ID: 16170366 [TBL] [Abstract][Full Text] [Related]
36. Gastric GISTs. Personal experience. Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602 [TBL] [Abstract][Full Text] [Related]
37. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210 [TBL] [Abstract][Full Text] [Related]
38. Kit expression in spindle cell rhabdomyosarcoma can possibly create a different approach for its tumorigenesis and therapy. Diniz G; Aktas S; Ortac R; Tunakan M; Unlu I; Vergin C Pathol Res Pract; 2006; 202(9):671-7. PubMed ID: 16860492 [TBL] [Abstract][Full Text] [Related]
39. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931 [TBL] [Abstract][Full Text] [Related]
40. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors]. Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]